The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome

Author:

Kelly Rebeca1ORCID,Aviles Diego1,Krisulevicz Catriona2,Hunter Krystal23,Krill Lauren1,Warshal David1,Ostrovsky Olga23ORCID

Affiliation:

1. Department of Gynecologic Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ 08103, USA

2. Cooper Medical School of Rowan University, Camden, NJ 08103, USA

3. Cooper Research Institute, Cooper University Healthcare, Camden, NJ 08103, USA

Abstract

High mortality rates in ovarian cancer have been linked to recurrence, metastasis, and chemoresistant disease, which are known to involve not only genetic changes but also epigenetic aberrations. In ovarian cancer, adipose-derived stem cells from the omentum (O-ASCs) play a crucial role in supporting the tumor and its tumorigenic microenvironment, further propagating epigenetic abnormalities and dissemination of the disease. Epigallocatechin gallate (EGCG), a DNA methyltransferase inhibitor derived from green tea, and Indole-3-carbinol (I3C), a histone deacetylase inhibitor from cruciferous vegetables, carry promising effects in reprograming aberrant epigenetic modifications in cancer. Therefore, we demonstrate the action of these diet-derived compounds in suppressing the growth of 3D ovarian cancer spheroids or organoids as well as post-treatment cancer recovery through proliferation, migration, invasion, and colony formation assays when compared to the synthetic epigenetic compound Panobinostat with or without standard chemotherapy. Finally, given the regulatory role of the secretome in growth, metastasis, chemoresistance, and relapse of disease, we demonstrate that natural epigenetic compounds can regulate the secretion of protumorigenic growth factors, cytokines, extracellular matrix components, and immunoregulatory markers in human ovarian cancer specimens. While further studies are needed, our results suggest that these treatments could be considered in the future as adjuncts to standard chemotherapy, improving efficiency and patient outcomes.

Funder

Camden Health Research Initiative

Publisher

MDPI AG

Subject

Molecular Biology,Biochemistry

Reference71 articles.

1. American Cancer Society (2023, January 05). Cancer Statistics Center. Available online: http://cancerstatisticscenter.cancer.org.

2. National Comprehensive Cancer Network (2023, January 10). Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2023). Available online: http://www.nccn.org/professionals/physician_gls/pdf/ovariancancer.pdf.

3. Ovarian cancer statistics, 2018;Torre;CA Cancer J. Clin.,2018

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

5. First-line treatment of advanced ovarian cancer: Current research and perspectives;Marchetti;Expert Rev. Anticancer. Ther.,2010

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3